China's Bloomage Forms Botox JV With Medytox Of South Korea

Bloomage BioTechnology formed a JV with South Korea's Medytox to market Medytox's version of the wrinkle treatment Botox (Botulinum Toxin) in China. The JV, which will be owned 50-50 by the two partners, will be called Medybloom. Bloomage is already involved in China's aesthetic care market as a producer of hyaluronic acid. It markets various grades of HA in China as orthopedic injections, ophthalmic solutions, cosmetic fillers, surgical anti-adhesion products and food supplements.

Help employers find you! Check out all the jobs and post your resume.